The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression
Open accessAbstract
Although high serum levels of galactose-deficient-IgA1 (an important biomarker of IgA nephropathy (IgAN)), are found in most patients with IgAN, their relationship to disease severity and progression remains unclear. To help clarify this we prospectively enrolled 275 patients with IgAN and followed them for a median of 47 months (range 12–96 months). Serum galactose-deficient-IgA1 was measured at the time of diagnosis using a lectin-based ELISA and renal survival was modeled using the Cox proportional hazards method. The serum levels of galactose-deficient-IgA1 were higher in patients with IgAN compared to those in healthy controls. Importantly, in adjusted analysis, higher levels of galactose-deficient-IgA1 were independently associated with a greater risk of deterioration in renal function with a hazard ratio of 1.44 per standard deviation of the natural log-transformed galactose-deficient-IgA1 concentration. In reference to the first quartile, the risk of kidney failure increased such that the hazard ratio for the second quartile was 2.47, 3.86 for the third, and 4.76 for the fourth quartile of the galactose-deficient-IgA1 concentration. Hence, elevated serum levels of galactose-deficient-IgA1 are associated with a poor prognosis in IgAN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial
Praga, M., Gutiérrez, E., González, E., Morales, E., & Hernández, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068460.37369.dc · Cited by 345
Cited by
New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura)
Heineke, M. H., Ballering, A. V., Jamin, A., Ben Mkaddem, S., Monteiro, R. C., & Van Egmond, M. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.009 · Cited by 329
Floege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
Magistroni, R., D’Agati, V. D., Appel, G. B., & Kiryluk, K. (2015) · Kidney International · doi:10.1038/ki.2015.252 · Cited by 302
Self-citationLafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060640 · Cited by 300
Self-citationIgA subclasses have different effector functions associated with distinct glycosylation profiles
Steffen, U., Koeleman, C. A., Sokolova, M. V., Bang, H., Kleyer, A., Rech, J., Unterweger, H., Schicht, M., Garreis, F., Hahn, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13992-8 · Cited by 263
Metadata
- Authors
- Zhao, N., Hou, P., Lv, J., Moldoveanu, Z., Li, Y., Kiryluk, K., Gharavi, A. G., Novak, J., & Zhang, H.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 82
- Issue
- 7
- Pages
- 790-796
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2058154849
- Cited by
- 248
- References
- 2
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. https://app.cochat.ai/papers/10.1038/ki.2012.197
- The paper
- Zhao, N., Hou, P., Lv, J., Moldoveanu, Z., Li, Y., Kiryluk, K., Gharavi, A. G., Novak, J., & Zhang, H. (2012). The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney International. https://doi.org/10.1038/ki.2012.197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.